China SXT Pharmaceuticals, Inc. (SXTC)

NASDAQ: SXTC · IEX Real-Time Price · USD
1.920
+0.010 (0.52%)
Feb 27, 2024, 4:00 PM EST - Market closed
0.52%
Market Cap 1.08M
Revenue (ttm) 33,621
Net Income (ttm) -5.93M
Shares Out 10.45M
EPS (ttm) -22.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 76,069
Open 1.900
Previous Close 1.910
Day's Range 1.880 - 1.950
52-Week Range 1.560 - 11.225
Beta 1.00
Analysts n/a
Price Target n/a
Earnings Date Aug 19, 2019

About SXTC

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, ... [Read more]

Sector Healthcare
IPO Date Jan 4, 2019
Employees 78
Stock Exchange NASDAQ
Ticker Symbol SXTC
Full Company Profile

Financial Performance

In 2022, SXTC's revenue was $33,621, a decrease of -90.09% compared to the previous year's $339,126. Losses were -$5.93 million, 3.46% more than in 2021.

Financial Statements

News

China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule

TAIZHOU, China, Oct. 26, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, m...

4 months ago - GlobeNewsWire

China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split

Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023 Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023

5 months ago - GlobeNewsWire

China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split

TAIZHOU, China, May 18, 2022 (GLOBE NEWSWIRE) --  China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, developmen...

1 year ago - GlobeNewsWire

China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million

TAIZHOU, China, March 14, 2022 (GLOBE NEWSWIRE) --  China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development,...

2 years ago - GlobeNewsWire

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC).

NEW YORK, NY / ACCESSWIRE / January 20, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for Chin...

2 years ago - Accesswire

China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment

TAIZHOU, China, Jan. 20, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, m...

2 years ago - GlobeNewsWire

China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares

TAIZHOU, China, Jan. 18, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, m...

2 years ago - GlobeNewsWire

China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares

TAIZHOU, China, Jan. 14, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, m...

2 years ago - GlobeNewsWire

China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin

TAIZHOU, China, Jan. 14, 2022 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, m...

2 years ago - PRNewsWire

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

TAIZHOU, China, Dec. 16, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC) announced today that on December 14, 2021, the Company received a notification l...

2 years ago - PRNewsWire

China SXT Pharmaceuticals, Inc. Obtained a New Pharmaceutical Manufacturing Permit and Passed Its GMP Compliance-Inspection

TAIZHOU, China, Oct. 18, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, m...

2 years ago - PRNewsWire

China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split

TAIZHOU, China, Feb. 19, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, m...

3 years ago - PRNewsWire